文献速递药物相互作用肝肾功能剂量调整

改善肾脏OCT2与MATE1/2-K转运体药物相互作用预测的挑战与机遇

Challenges and Opportunities for Improved Drug-Drug Interaction Predictions for Renal OCT2 and MATE1/2-K Transporters.
PubMed 文献 · Clin Pharmacol Ther · 2022-06-25

本文综述了肾脏有机阳离子转运体2(OCT2)和多药及毒素外排转运体1及2-K(MATE1/2-K)介导的药物相互作用(DDI)预测问题。文章评估了体外实验设计和预测模型(包括监管机构提出的静态模型和基于生理的药代动力学模型)对临床DDI风险评估的影响,指出不同体外实验设计(底物和细胞系统)强烈影响半数抑制浓度值,导致实验室间高变异性,且缺乏敏感指示底物和特异性抑制剂,需要复杂模型评估临床DDI风险。

要点

  • 体外实验设计(底物和细胞系统)影响OCT2/MATE1/2-K的IC50值,导致实验室间高变异性。
  • 缺乏敏感指示底物和特异性抑制剂,需用复杂模型评估临床DDI风险。
  • 当前体外方法和模型可能过度预测DDI风险,导致不必要的临床评估。

核心结论

  • 不同体外实验设计(底物和细胞系统)强烈影响OCT2和MATE1/2-K的IC50值,导致实验室间高变异性。
  • 缺乏敏感指示底物和特异性抑制剂,需使用复杂模型评估临床DDI风险。
  • 当前体外实验设计和建模实践可能导致不必要的临床评估。

研究设计与样本

  • 综述评估体外和临床数据及预测模型(包括监管机构静态模型和PBPK模型)。

主要发现

  • 体外实验设计(底物和细胞系统)影响IC50值,导致实验室间高变异性。
  • 缺乏敏感指示底物和特异性抑制剂,需复杂模型评估临床DDI风险。
  • 大量药物和NMEs体外抑制OCT2/MATE1/2-K但缺乏临床显著效应转化。

关键数值与推荐

  • 监管机构已提供指南评估OCT2和MATE1/2-K的DDI风险。
  • 静态模型和PBPK模型用于提供临床风险背景。

临床怎么用

  • 临床药学需关注OCT2/MATE1/2-K介导的DDI风险,结合体外数据和模型评估。
  • 当前体外方法和模型可能高估风险,需谨慎解读以避免不必要的临床评估。

局限性

  • 体外实验设计(底物和细胞系统)差异导致IC50值高变异性。
  • 缺乏敏感指示底物和特异性抑制剂,需复杂模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transporters contribute to renal elimination of drugs; therefore drug disposition can be impacted if transporters are inhibited by comedicant drugs. Regulatory agencies have provided guidelines to assess potential drug-drug interaction (DDI) risk for renal organic cation transporter 2 (OCT2) and multidrug and toxin extrusion 1 and 2-K (MATE1/2-K) transporters. Despite this, there are challenges with translating in vitro data using currently available tools to obtain a quantitative assessment of DDI risk in the clinic. Given the high number of drugs and new molecular entities showing in vitro inhibition toward OCT2 and/or MATE1/2-K and the lack of translation to clinically significant effects, it is reasonable to question whether the current in vitro assay design and modeling practice has led to unnecessary clinical evaluation. The aim of this review is to assess and discuss available in vitro and clinical data along with prediction models intended to provide clinical context of risk, including static models proposed by regulatory agencies and physiologically-based pharmacokinetic models, in order to identify best practices and areas of future opportunity. This analysis highlights that different in vitro assay designs, including substrate and cell systems used, strongly influence the derived concentration of drug producing 50% inhibition values and contribute to high variability observed across laboratories. Furthermore, the lack of sensitive index substrates coupled with specific inhibitors for individual transporters necessitates the use of complex models to evaluate clinical DDI risk.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Krishnan S, Ramsden D, Ferguson D, et al. Challenges and Opportunities for Improved Drug-Drug Interaction Predictions for Renal OCT2 and MATE1/2-K Transporters. Clin Pharmacol Ther. 2022. PMID: 35598119. doi:10.1002/cpt.2666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。